EBV LMP2A TCR-T-cell therapy
/ Fudan University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 20, 2022
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Fudan University
New P1 trial • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1